Dbv

Edit

DBV Technologies to Participate in Upcoming March Investor Conferences (DBV Technologies SA)

Public Technologies 04 Mar 2026

DBV TECHNOLOGIES ... DBV Technologies to Participate in Upcoming March Investor Conferences. DBV Technologies (Euronext. DBV - ISIN ... About DBV Technologies ... DBV Technologies is committed to transforming the care of food allergic people ... DBV Technologies ... DBV.

Edit

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 (DBV Technologies SA)

Public Technologies 03 Mar 2026

). 03 Mar 2026 22.30 CET. Subscribe ... DBV TECHNOLOGIES ... DBV Technologies S.A ... DBV TECHNOLOGIES ... DBV ... DBV Technologies SA published this content on March 03, 2026, and is solely responsible for the information contained herein.

Edit

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting (Form 8-K) (DBV Technologies SA)

Public Technologies 02 Mar 2026

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting • ... DBV Technologies (Euronext. DBV - ISIN ... of DBV Technologies ... About DBV Technologies.

Edit

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 ...

Norfolk Daily News 01 Mar 2026

Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study ... .

Edit

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting (DBV Technologies SA)

Public Technologies 10 Feb 2026

DBV Technologies SA published this content on February 10, 2026, and is solely ...

Edit

Statement of Changes in Beneficial Ownership (Form 4) (DBV Technologies SA)

Public Technologies 02 Feb 2026

) FORM 4 ... 0.5 ... 2 ... DBV Technologies S.A ... C/O DBV TECHNOLOGIES S.A., 107, AVENUE DE LA REPUBLIQUE 3 ... 6 ... C/O DBV TECHNOLOGIES S.A ... DBV Technologies SA published this content on February 02, 2026, and is solely responsible for the information contained herein.

Edit

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing (Form 8-K) (DBV Technologies SA)

Public Technologies 20 Jan 2026

2 https.//dbv-technologies.com/press_releases/dbv-technologies-announces-financing-of-up-to-306-9-million-e284-5-million-to-advance-viaskin-.

Edit

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing (DBV Technologies SA)

Public Technologies 16 Jan 2026

2https.//dbv-technologies.com/press_releases/dbv-technologies-announces-financing-of-up-to-306-9-million-e284-5-million-to-advance-viaskin-peanut-patch-through-biologics-license-application-submission-and-u-s-commercial-launch-if-appr/.

Edit

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (DBV Technologies SA)

Public Technologies 07 Jan 2026

DBV TECHNOLOGIES ... Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF. DBV Technologies (Euronext. DBV - ISIN ... 74,580 DBV Technologies shares, € 527,891.63 ... 41,159 DBV Technologies shares, € 432,367.25 ... About DBV Technologies ... DBV.

Edit

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Nasdaq Globe Newswire 07 Jan 2026

AMF Regulated Information. Ch�tillon, France, January 7, 2026 ... .

Edit

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years (Form 8-K) (DBV Technologies SA)

Public Technologies 16 Dec 2025

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years • ... DBV to host a conference call today at 5.00 p.m ... DBV Technologies (Euronext. DBV - ISIN ... DBV, ISIN code.

Podcasts:

Latest News for: dbv

DBV Technologies to Participate in Upcoming March Investor Conferences (DBV Technologies SA)

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 (DBV Technologies SA)

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting (Form 8-K) (DBV Technologies SA)

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 ...

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting (DBV Technologies SA)

Statement of Changes in Beneficial Ownership (Form 4) (DBV Technologies SA)

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing (Form 8-K) (DBV Technologies SA)

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing (DBV Technologies SA)

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (DBV Technologies SA)

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years (Form 8-K) (DBV Technologies SA)

Article Search

EXPLORE WN.com